Donna R. Grogan

TL;DR: This study provides Class II evidence that 20 mg tafamidis QD was associated with no difference in clinical progression in patients with TTR-FAP, as measured by the NIS-LL and the Norfolk QOL-DN score, supporting the hypothesis that preventing TTR dissociation can delay peripheral neurologic impairment.

TL;DR: The current findings support further investigation of the role of wtTTR in the pathophysiology of HFpEF and support an emerging understanding of the pathogenesis of the amyloidoses.

TL;DR: Tafamidis was well tolerated, with the reduced rate of neurologic deterioration sustained over 30 months, and slowed neurologic impairment in patients previously given placebo, but treatment benefits were greater when taf amidis was begun earlier.

TL;DR: This initial experience with intravenous cangrelor during PCI suggests an acceptable risk of bleeding and adverse cardiac events while achieving rapid, reversible inhibition of platelet aggregation via competitive binding to the ADP P2Y12 platelet receptor with less prolongation of bleeding time then the glycoprotein IIb/IIIa receptor antagonist abciximab.

TL;DR: Disease progression, morbidity, and mortality were observed in ATTR cardiomyopathy, particularly due to V122I, over a short duration, given the prevalence of this mutation in at-risk African American patients.